Revance Therapeutics Regains All Worldwide Rights to Its Botulinum Toxin Products; Will Make Upfront Payment of $7M, Up to Added $18M Payments; Medicis Will Keep Equity Stake in Revance

Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation MRX concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A. As part of the settlement, all worldwide rights to develop and commercialize both products across all indications will be returned to Revance. The agreement will also resolve the outstanding litigation between the companies.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDALegal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!